Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Ute Hegenbart, Niklas Fuhr, Laura Huber, Christoph Kimmich, Kaya Veelken, Tobias Dittrich, Rita Ziehl, Fabian aus dem Siepen, Alexander Carpinteiro, Timon Hansen, Carsten Müller-Tidow, Axel Benner, Stefan Schönland

Blood (2021) 138 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2021-152713

Published: 2021

Journal Articles

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Marco Basset, MD, Christoph Kimmich, Tobias Dittrich, MD, Kaya Veelken, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Anja Seckinger, MD, Anna Jauch, Carsten Mueller-Tidow, MD, Ute Hegenbart, MD, Stefan Schönland, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142701

Published: 2020

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

Anja Seckinger, Ute Hegenbart, Susanne Beck, Martina Emde, Tilmann Bochtler, Christoph Kimmich, Carsten Müller-Tidow, MD, Anna Jauch, PhD, Stefan Schönland, Dirk Hose, MD

Blood (2018) 132 (Supplement 1): 187.

https://doi.org/10.1182/blood-2018-187

Published: 2018

Journal Articles

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Paolo Milani, Stefan Schönland, Giampaolo Merlini, Christoph Kimmich, Andrea Foli, Tobias Dittrich, Marco Basset, Carsten Müller-Tidow, Tilmann Bochtler, Giovanni Palladini, Ute Hegenbart

Blood (2018) 132 (18): 1988–1991.

https://doi.org/10.1182/blood-2018-04-845396

Published: 2018

Includes: Supplemental data

Journal Articles

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich, Stefan O. Schönland

Blood (2018) 131 (3): 368–371.

https://doi.org/10.1182/blood-2017-09-806463

Published: 2018

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Daratumumab Monotherapy in Thirty-Two Heavily Pre-Treated Patients with Advanced Systemic Light-Chain Amyloidosis

Christoph Kimmich, MD, Stefan Schönland, MD, Rita Ziehl, Anthony D. Ho, Tobias Dittrich, MD, Carsten Müller-Tidow, Ute Hegenbart

Blood (2017) 130 (Supplement 1): 1837.

https://doi.org/10.1182/blood.V130.Suppl_1.1837.1837

Published: 2017

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Tobias Dittrich, Tilmann Bochtler, Christoph Kimmich, Natalia Becker, Anna Jauch, Hartmut Goldschmidt, Anthony D. Ho, Ute Hegenbart, Stefan O. Schönland

Blood (2017) 130 (5): 632–642.

https://doi.org/10.1182/blood-2017-02-767475

Published: 2017

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Tilmann Bochtler, Ute Hegenbart, Christina Kunz, Axel Benner, Christoph Kimmich, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Martin Granzow, Peter Dreger, Anthony D. Ho, Anna Jauch, Stefan O. Schönland

Blood (2016) 128 (4): 594–602.

https://doi.org/10.1182/blood-2015-10-676361

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Tobias Dittrich, MD, Ute Hegenbart, MD, Tilmann Bochtler, MD, Christoph Kimmich, MD, Anna Jauch, Prof., Arnt Kristen, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD, Stefan Schönland, MD

Blood (2015) 126 (23): 1790.

https://doi.org/10.1182/blood.V126.23.1790.1790

Published: 2015

Journal Articles

Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry

Stefan Schönland, MD, Ute Hegenbart, MD, Christoph Kimmich, Katarina Lisenko, MD, Dirk Hose, MD PhD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Anthony D. Ho, Prof., MD FRCPC, Michael Hundemer, MD

Blood (2014) 124 (21): 2068.

https://doi.org/10.1182/blood.V124.21.2068.2068

Published: 2014

Journal Articles

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

Giovanni Palladini, Ute Hegenbart, Paolo Milani, Christoph Kimmich, Andrea Foli, Anthony D. Ho, Marta Vidus Rosin, Riccardo Albertini, Remigio Moratti, Giampaolo Merlini, Stefan Schönland

Blood (2014) 124 (15): 2325–2332.

https://doi.org/10.1182/blood-2014-04-570010

Published: 2014

Includes: Supplemental data

Journal Articles

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Stefan O Schonland, MD, Tilmann Bochtler, MD, Axel Benner, Marianne Gawlik, Christoph Kimmich, Arnt V Kristen, Jörg Beimler, Anthony D. Ho, MD, Ute Hegenbart, MD

Blood (2013) 122 (21): 1993.

https://doi.org/10.1182/blood.V122.21.1993.1993

Published: 2013

Journal Articles

Treatment of AL Amyloidosis with Bendamustine

Giovanni Palladini, Stefan O Schonland, MD, Paolo Milani, Christoph Kimmich, MD, Andrea Foli, Tilmann Bochtler, MD, Giampaolo Merlini, Ute Hegenbart, MD

Blood (2012) 120 (21): 4057.

https://doi.org/10.1182/blood.V120.21.4057.4057

Published: 2012

NARROW

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

AL Amyloidosis — Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Daratumumab Monotherapy in Thirty-Two Heavily Pre-Treated Patients with Advanced Systemic Light-Chain Amyloidosis

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis

Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Treatment of AL Amyloidosis with Bendamustine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only